ベバシズマブ硝子体内注射が奏効したIrvine-Gass症候群の2例

Intravitreal injection of bevacizumab was effective in two cases of Irvine-Gass syndrome

要約　目的：ベバシズマブの硝子体内注射が奏効したIrvine-Gass症候群2例の報告。症例：73歳と69歳の男性が超音波水晶体乳化吸引術と眼内レンズ移植術を受けた。術直後の視力は0.8と1.2であったが，それぞれ3週間後と2か月後に0.2と0.6に低下した。いずれにも囊胞様黄斑浮腫と中心窩の肥厚があり，Irvine-Gass症候群と診断された。ベバシズマブ1.25mgを2例の硝子体内に注射した。いずれも2週間後と1週間後に囊胞様黄斑浮腫は消失し，視力はそれぞれ0.4と1.2に改善した。13か月後と22か月後まで再発はない。結論：Irvine-Gass症候群に対し，ベバシズマブの硝子体注射が奏効する可能性がある。

Abstract.　Purpose：To report two cases of Irvine-Gass syndrome that responded to intravitreal injection of bevacizumab. Cases and Findings：Two males,aged 73 and 69 years,received phacoemulsification with intraocular lens implantation. Visual acuity improved to 0.8 and 1.2 but decreased to 0.2 and 0.6 after 3 weeks and 2 months respectively. Both cases showed cystoid macular edema（CME）and thickened fovea,leading to the diagnosis of Irvine-Gass syndrome. Intravitreal injection of bevacizumab was followed by resolution of CME after 2 and 1 week respectively. Visual acuity improved to 0.4 and 1.2 respectively. There has been no recurrence for 13 and 22 months until present. Conclusion：Intravitreal injection of bevacizumab may be effective for Irvine-Gass syndrome.